Navigation Links
AutoGenomics CYP 2C19 Test Used in Study to Personalize Clopidogrel (Plavix) Dosing in Patients
Date:1/22/2009

CARLSBAD, Calif., Jan. 22 /PRNewswire/ -- AutoGenomics, a leader in providing automated molecular testing solutions announced today that its CYP450 2C19 assay was used in a study to demonstrate the value of genetic variants in dosing of the antiplatelet agent, Plavix.

Plavix, commonly known as Clopidogrel, is an anti-platelet agent used in the treatment for coronary artery disease, peripheral vascular disease and cerebrovascular disease. To realize the antiplatelet effect, Clopidogrel requires biotransformation to an active metabolite by cytochrome P-450 enzymes.

"Personalizing Clopidogrel dosing using pharmacogenetics may be an effective method of rationalizing treatment. In a recent study we used the AutoGenomics 2C19 test to screen for polymorphisms associated with a reduced response to the drug" said Dr. Mark Webster, Director of Cardiac Catheterization at the Auckland City Hospital. His co-investigator Dr. Patrick Gladding said that "other studies have shown that patients treated with Clopidogrel with a reduced function CYP C219 genetic variant had lower levels of the active metabolite resulting in a reduced antiplatelet response to the drug and a three-fold risk of stent thrombosis."

"We are pleased that Dr. Webster and Dr. Gladding have taken a pioneering role in assessing the role of genetic variants in Clopidogrel dosing to ensure patient safety. The AutoGenomics platform enables the rapid testing of such CYP 450 tests including CYP 2C9, CYP 3A4 & CYP 3A5 that have been quoted in recent publications as factors that could be of interest in drug dosing" said Ramanath Vairavan, Senior Vice President at AutoGenomics. He further said "that recent studies published in the New England Journal of Medicine indicated that about 30% of the patients had at least one CYP 2C19 reduced function genetic variant". With such high incidence of these reduced functional alleles it is gratifying to note the active role that FDA is taking to re-label these drugs and help realize the promise of personalized medicine to ensure drug efficacy and patient safety".

About AutoGenomics

AutoGenomics Inc., a privately held company based in Carlsbad, CA, has developed the first automated, microarray based multiplexing diagnostic platform that can be used to assess disease signatures with novel genomic and proteomic markers in the area of genetic disorders, infectious disease, cancer and pharmacogenetics. With the discovery of genes and their link to various disease states the platform has the versatility to revolutionize the way patients are diagnosed, monitored and managed leading to the era of personalized medicine. www.autogenomics.com


'/>"/>
SOURCE AutoGenomics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AutoGenomics Receives FDA Clearance for its INFINITI(TM) Warfarin Assay
2. AutoGenomics Receives a Key European Patent for HPV Detection
3. AutoGenomics INFINITI Analyzer Receives Artistic Design Award
4. AutoGenomics, Inc. Files Registration Statement for Initial Public Offering
5. Penn study finds pro-death proteins required to regulate healthy immune function
6. New study shows promise in reducing surgical risks associated with surgical bleeding
7. Study, meta-analysis examine factors associated with death from heatstroke
8. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
9. Study says COPD testing is not measuring up
10. Preclinical study suggests organ-transplant drug may aid in lupus fight
11. Ability to cope with stress can increase good cholesterol in older white men, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June 14 ... The article goes on to state that individuals are now more comfortable seeking to ... operations such as calf and cheek reduction. The Los Angeles area medical group, Beverly ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... ... ... People across the U.S. are sharpening their pencils and honing their writing ... which patients and their families pay tribute to a genetic counselor by nominating him ... Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In April, Genome ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Calif. , June 23, 2016 Any dentist ... many challenges of the current process. Many of them do ... of the technical difficulties and high laboratory costs involved. And ... to offer it at such a high cost that the ... it. Dr. Parsa Zadeh , founder of ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... June 23, 2016 , , ... July 7, 2016 , , , , LOCATION: , , ... , , , EXPERT PANELISTS:  , , , Frost & ... Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, ... The global pharmaceutical industry is witnessing an exceptional era. Several new ...
Breaking Medicine Technology: